David Geliebter
Co-Founder and Executive Chairman at Critical Diagnostics, novel biomarkers developer to help physicians optimize patient care in cardiovascular diseases, while containing healthcare costs.
David is an accomplished serial entrepreneur with five decades of experience starting and growing businesses. Prior to founding Critical Diagnostics, David started and ran the Carson Group, one of the world's most successful financial information and advisory companies. Additionally, he was a founding principal and President of Evolution Capital, a healthcare investment bank. Both Carson Group and Evolution Capital were sold to the Thomson Corporation (now Thomson-Reuters) in 2000. David is the Managing Partner of Carrot Capital Healthcare Ventures and is on the board of Remedy Pharmaceuticals. David is a recipient of the Ernst & Young Entrepreneur of the Year Award.
David is an accomplished serial entrepreneur with five decades of experience starting and growing businesses. Prior to founding Critical Diagnostics, David started and ran the Carson Group, one of the world's most successful financial information and advisory companies. Additionally, he was a founding principal and President of Evolution Capital, a healthcare investment bank. Both Carson Group and Evolution Capital were sold to the Thomson Corporation (now Thomson-Reuters) in 2000. David is the Managing Partner of Carrot Capital Healthcare Ventures and is on the board of Remedy Pharmaceuticals. David is a recipient of the Ernst & Young Entrepreneur of the Year Award.